



(51) International Patent Classification:
A61K 9/14 (2006.01)

(21) International Application Number:
PCT/EP2016/080111

(22) International Filing Date:
7 December 2016 (07.12.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/264,792 8 December 2015 (08.12.2015) US

(71) Applicants: ARDEA BIOSCIENCES, INC. [US/US];
9390 Towne Centre Drive, San Diego, California 92121
(US). ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje
(SE).

(72) Inventors: REILAND WAKEMAN, Joanne; 10952
Riesling Drive, San Diego, California 92131 (US).
ROWLINGS, Colin; 5484 Shannon Ridge Lane, San
Diego, California 92130 (US). LIU, Sha; 5827 Lopez
Canyon Way, San Diego, California 92126 (US). BURKE,
Gerry; 4427 Corte Morea, San Diego, California 92129
(US). VON CORSWANT, Christian; AstraZeneca R&D,
431 83 Mölndal (SE). TANNERGREN, Christer; As-
traZeneca R&D, 431 83 Mölndal (SE). HJÄRTSTAM,
Johan; AstraZeneca R&D, 431 83 Mölndal (SE).

(74) Agents: MATHARU, Balvinder Singh et al.; HGF Lim-
ited, 4th Floor, Merchant Exchange, 17-19 Whitworth
Street West, Manchester M1 5WG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1

(57) Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4- cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the "Agent"), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the pre-
paration of said compositions.

